Interferon‐α‐2a with or without 13‐cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

BACKGROUND In patients with metastatic renal cell carcinoma (MRCC), interferon‐α (IFN) monotherapy leads to response rates of 5–15%, dependent on the selection of patients. In 1995, preclinical and clinical data indicated an improvement of these results if IFN was combined with 13‐cis retinoic acid...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancer 2004-08, Vol.101 (3), p.533-540
Hauptverfasser:	Fosså, Sophie D., Mickisch, Gerald H. J., De Mulder, Pieter H. M., Horenblas, Simon, van Oosterom, Allan T., van Poppel, Hein, Fey, Martin, Croles, Jelle J., de Prijck, Linda, Van Glabbeke, Martine
Format:	Artikel
Sprache:	eng
Schlagworte:	13‐cis retinoic acid interferon‐α metastatic renal cell carcinoma response evaluation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!